niagen生物科学公司2025年季度报告

NIAGEN BIOSCIENCE, INC.(Exact Name of Registrant as Specified in its Charter) Item 2. Management’s Discussion and Analysis of Financial Condition and Results of OperationsItem 3. Quantitative and Qualitative Disclosures About Market Risk Item 1. Legal Proceedings Item 1A. Risk FactorsItem 5. Other informationItem 6. Exhibits Basis of Presentation:The accompanying Unaudited Condensed Consolidated Financial Statements have been prepared in accordancewith accounting principles generally accepted in the United States of America (“generally accepted accounting principles” or “GAAP”) for interim financial information and the instructions to Form 10-Q and Regulation S-X promulgated under the SecuritiesExchange Act of 1934, as amended (the “Exchange Act”). Certain information and footnote disclosures normally included in financialstatements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. In the opinionof management, the interim Unaudited Condensed Consolidated Financial Statements include all adjustments, including normalrecurring adjustments, necessary for a fair presentation of the financial condition, results of operations and cash flows for such periods.Results of operations for any interim period are not necessarily indicative of results for any other interim period or for the full year. Basis of Consolidation:The accompanying Unaudited Condensed Financial Statements and notes thereto have been prepared on aconsolidated basis and reflect the consolidated financial position of the Company and its wholly owned subsidiaries. All significantintercompany balances and transactions have been eliminated from these financial statements.Significant Accounting Policies:There have been no changes to the Company’s significant accounting policies described in theCompany’s 2024 Annual Report on Form 10-K that have had a material impact on the Company’s Unaudited Condensed ConsolidatedFinancial Statements and related notes. Disclosure Update and Simplification Initiative,” to amend certain disclosure and presentation requirements for a variety of topicswithin the Accounting Standards Codification (ASC). These amendments align the requirements in the ASC to the removal of certain disclosure requirements set out in Regulation S-X and Regulation S-K, announced by the SEC. The effective date for each amendedtopic in the ASC is either the date on which the SEC’s removal of the related disclosure requirement from Regulation S-X orRegulation S-K becomes effective, or on June 30, 2027, if the SEC has not removed the requirements by that date. Early adoption isprohibited. The Company is currently evaluating the impact that the adoption of ASU 2023-06 may have on its consolidated financialstatements and disclosures. 2023-09 is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09address investor requests for enhanced income tax information primarily through changes to the rate reconciliation and income taxes December 15, 2024. Early adoption and retrospective application are permitted. The Company is currently evaluating the impact ofthis standard on its consolidated financial statements and related disclosures. entities within the scope of the affected accounting guidance, but in most instances the references removed are extraneous and notrequired to understand or apply the guidance. ASU 2024-02 is effective for annual periods beginning after December 15, 2024, withearly adoption permitted. While the Company is currently evaluating the impact of this standard, it is not expected to have a significant In November 2024, the FASB issued ASU 2024-03, “Income Statement (Topic 220): Reporting Comprehensive Income - Expense additional information about certain expense categories, including purchases of inventory, employee compensation, depreciation,amortization, and depletion, in both interim and annual financial statements. The amendments in this ASU will be effective for annualperiods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption ispermitted and is effective on either a prospective basis or retrospective basis. The Company is currently evaluating the impact of thisNote 3.Liquidity activities. For thethree months ended March31, 2025, the Company had net income of$5.1million and the Company’s operatingactivitiesprovidedcash of$7.9million. As of March31, 2025, the Company had unrestricted cash and cash equivalents of $55.5 million which consists of bank deposits and short-term investments, including highly liquid investment-grade debt instruments with anoriginal maturity of three months or less.The fair value of the Company’s cash and cash equivalents is derived using Level 1 inputs.Management evaluated these conditions and anticipates that its current unrestricted cash and cash equivalents and cash to be generatedfrom net sales will be suffi